Cargando…

The Exceptional Oncogenicity of HTLV-1

Human T-cell leukemia virus-1 (HTLV-1) is the first pathogenic human retrovirus identified in 1979 by the Gallo group. HTLV-1 causes fatal T-cell leukemia (adult T cell leukemia) and a progressive myelopahy (HTLV-1-associated myelopathy/ tropical spastic paraparesis, HAM/TSP) and other disorders. Si...

Descripción completa

Detalles Bibliográficos
Autores principales: Tagaya, Yutaka, Gallo, Robert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539117/
https://www.ncbi.nlm.nih.gov/pubmed/28824561
http://dx.doi.org/10.3389/fmicb.2017.01425
_version_ 1783254421026635776
author Tagaya, Yutaka
Gallo, Robert C.
author_facet Tagaya, Yutaka
Gallo, Robert C.
author_sort Tagaya, Yutaka
collection PubMed
description Human T-cell leukemia virus-1 (HTLV-1) is the first pathogenic human retrovirus identified in 1979 by the Gallo group. HTLV-1 causes fatal T-cell leukemia (adult T cell leukemia) and a progressive myelopahy (HTLV-1-associated myelopathy/ tropical spastic paraparesis, HAM/TSP) and other disorders. Since the discovery of HTLV-1, several other microorganisms are demonstrated to cause cancer in humans. In this article, we investigated the oncogenic capacity of HTLV-1, in comparison with those of other oncoviruses and one oncobacterium (Helicobacter pylori, H. Pylori) based on published literature. We conclude here that HTLV-1 is one of the most and may be the most carcinogenic among them and arguably one of the most potent of the known human carcinogens. This fact has not been noted before and is particularly important to justify why we need to study HTLV-1 as an important model of human viral oncogenesis.
format Online
Article
Text
id pubmed-5539117
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-55391172017-08-18 The Exceptional Oncogenicity of HTLV-1 Tagaya, Yutaka Gallo, Robert C. Front Microbiol Microbiology Human T-cell leukemia virus-1 (HTLV-1) is the first pathogenic human retrovirus identified in 1979 by the Gallo group. HTLV-1 causes fatal T-cell leukemia (adult T cell leukemia) and a progressive myelopahy (HTLV-1-associated myelopathy/ tropical spastic paraparesis, HAM/TSP) and other disorders. Since the discovery of HTLV-1, several other microorganisms are demonstrated to cause cancer in humans. In this article, we investigated the oncogenic capacity of HTLV-1, in comparison with those of other oncoviruses and one oncobacterium (Helicobacter pylori, H. Pylori) based on published literature. We conclude here that HTLV-1 is one of the most and may be the most carcinogenic among them and arguably one of the most potent of the known human carcinogens. This fact has not been noted before and is particularly important to justify why we need to study HTLV-1 as an important model of human viral oncogenesis. Frontiers Media S.A. 2017-08-02 /pmc/articles/PMC5539117/ /pubmed/28824561 http://dx.doi.org/10.3389/fmicb.2017.01425 Text en Copyright © 2017 Tagaya and Gallo. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Tagaya, Yutaka
Gallo, Robert C.
The Exceptional Oncogenicity of HTLV-1
title The Exceptional Oncogenicity of HTLV-1
title_full The Exceptional Oncogenicity of HTLV-1
title_fullStr The Exceptional Oncogenicity of HTLV-1
title_full_unstemmed The Exceptional Oncogenicity of HTLV-1
title_short The Exceptional Oncogenicity of HTLV-1
title_sort exceptional oncogenicity of htlv-1
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539117/
https://www.ncbi.nlm.nih.gov/pubmed/28824561
http://dx.doi.org/10.3389/fmicb.2017.01425
work_keys_str_mv AT tagayayutaka theexceptionaloncogenicityofhtlv1
AT gallorobertc theexceptionaloncogenicityofhtlv1
AT tagayayutaka exceptionaloncogenicityofhtlv1
AT gallorobertc exceptionaloncogenicityofhtlv1